<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799028</url>
  </required_header>
  <id_info>
    <org_study_id>20.10.INF</org_study_id>
    <nct_id>NCT04799028</nct_id>
  </id_info>
  <brief_title>Evaluation of Toddler Milk Containing L.Reuteri, Galacto-oligosaccharides and Palm-Oil Free Fat Blend</brief_title>
  <acronym>BeBOP</acronym>
  <official_title>Evaluation of Toddler Milk Containing L.Reuteri, Galacto-oligosaccharides and Palm-Oil Free Fat Blend On Bone Metabolism Among Healthy Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of experimental growing up milk (EXPL)&#xD;
      as compared to traditional children's fortified milk (CTRL) fed for 6 months on bone mass&#xD;
      index.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind controlled clinical trial was chosen to study the effects of&#xD;
      toddler milk containing L. reuteri and GOS (4g/L) and a low sn-1, -3 fat blend when compared&#xD;
      to a control formula. There is an additional unblinded habitual intake reference group (REF)&#xD;
      for &quot;real-world&quot; comparison (including 58% non-dairy drinkers according to observational&#xD;
      data).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study is a double-blinded study. The identity of specific product will be masked to subjects, support staff, investigators and sponsor's personnel except the manufacture and quality unit at Nestle (production factory).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Speed of sound (SOS)</measure>
    <time_frame>Day 1, Day 90, Day 180</time_frame>
    <description>Speed of sound (SOS) using a quantitative ultrasound methods measured by Pediatric Sunlight 9000 device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GI tolerance and stooling patterns</measure>
    <time_frame>Day 1</time_frame>
    <description>Stool patterns including stool frequency will be recorded retrospectively via 24-hour GI Symptom and Behavior Recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI tolerance and stooling patterns</measure>
    <time_frame>Day 1</time_frame>
    <description>Stool patterns including stool consistency will be recorded retrospectively via 24-hour GI Symptom and Behavior Recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI tolerance and stooling patterns</measure>
    <time_frame>Day 90, Day 180</time_frame>
    <description>Stool patterns including stool frequency will be recorded using 3-day GI Symptom and Behavior diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI tolerance and stooling patterns</measure>
    <time_frame>Day 90, Day 180</time_frame>
    <description>Stool patterns including stool consistency will be recorded using 3-day GI Symptom and Behavior diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI tolerance and stooling patterns</measure>
    <time_frame>Day 1, Day 90, Day 180</time_frame>
    <description>Parent perceptions of GI symptoms using parent-reported questionnaire Toddler Gut Comfort Questionnaire (GCQ) using VAS from 1-Never to 6-Always with higher scores indicating increasing GI burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI tolerance and stooling patterns</measure>
    <time_frame>Day 1, Day 90, Day 180</time_frame>
    <description>Parent perceptions of GI-related behaviors using parent-reported questionnaire Toddler Gut Comfort Questionnaire (GCQ) using VAS from 1-Never to 6-Always with higher scores indicating increasing GI burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool analyses</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Excretion of fecal calcium fatty acid soaps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool analyses</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Measurement of stool calcium content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum vitamin D</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Measured by serum 25[OH]D concentration requiring 1mL of whole blood sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine and Blood bone turnover markers</measure>
    <time_frame>Day 1, Day 180 (EXPL and CTRL groups only)</time_frame>
    <description>Bone accretion markers in urinary [C-terminal cross-linked telopeptides of type I collagen (CTX)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine and Blood bone turnover markers</measure>
    <time_frame>Day 1, Day 180 (EXPL and CTRL groups only</time_frame>
    <description>serum procollagen type I N-terminal propeptide (PINP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Gut microbiota analyzed for microbiome composition and diversity using next generation shotgun metagenomics sequencing, requiring 3g of stool sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool analyses</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Determination of fecal short chain fatty acids (SCFAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool analyses</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Fecal pH and metabolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool analyses</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Fecal markers of gut health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical strength</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Hand grip test (Jamar hand dynamometer) tailored for toddlers will be used as previously described Bohannon et al Pediatric Physical Therapy 2017.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>serum vitamin B concentration requiring 2 mL of whole blood sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake patterns</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Intake patterns are assessed using parent-reported questionnaire Child Eating Behavior Questionnaire including variety of food groups consumed as well as behaviors rated from Never to Always.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child quality of life using validated ITQOL SF-47 questionnaire</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>assessed using the parent-reported questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outdoor Playtime</measure>
    <time_frame>Day 1 and Day 180</time_frame>
    <description>Assessed using parent-reported questionnaire on Outdoor Playtime recording number of hours child spent outside.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child temperament</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Children's Behavior Questionnaire (very short form), consisting of 36 questions and 3 scales on child temperament domains Surgency, Negative Affect and Effort Control with each question ranging 1-extremely untrue to 7- extremely true of parent observing various behaviors.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Measurement of weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Measurement of height</description>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Day 1, Day 180</time_frame>
    <description>Measurement of head circumference</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints</measure>
    <time_frame>Day 1, Day 180 and follow up of 14 days after last intake of study products</time_frame>
    <description>Standard AEs reporting for safety assessment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">273</enrollment>
  <condition>Toddlers Bone Metabolism</condition>
  <arm_group>
    <arm_group_label>Traditional children's fortified cow's milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>New toddler milk with synbiotics and fat blend</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddlers consuming habitual diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Traditional cow's milk</intervention_name>
    <description>Fortified cow's milk</description>
    <arm_group_label>Traditional children's fortified cow's milk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental milk</intervention_name>
    <description>Milk with synbiotics and fat blend</description>
    <arm_group_label>New toddler milk with synbiotics and fat blend</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Habitual diet</intervention_name>
    <description>Habitual diet</description>
    <arm_group_label>Toddlers consuming habitual diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All subjects must comply with all the following criteria:&#xD;
&#xD;
          1. Written informed consent has been obtained from the parent(s)/legally acceptable&#xD;
             representative (LAR).&#xD;
&#xD;
          2. Singleton, full-term gestational birth (≥ 37 completed weeks of gestation), with a&#xD;
             birth weight of ≥ 2.5 kg and ≤ 4.5 kg.&#xD;
&#xD;
          3. Child is between 24 months ±1 week to 36 months ±1 week.&#xD;
&#xD;
          4. Child is not currently consuming nor has consumed any formulas or taking any&#xD;
             supplements with pre- or probiotics at enrolment or in the past month.&#xD;
&#xD;
          5. Child's parent(s)/guardian is of legal age of consent, must understand the informed&#xD;
             consent and other study documents, and is willing and able to fulfill the requirements&#xD;
             of the study protocol.&#xD;
&#xD;
        All subjects presenting one or more of the following criteria are excluded from&#xD;
        participation in the study:&#xD;
&#xD;
          1. Chronic infectious, metabolic, genetic illness or other disease including any&#xD;
             condition that impacts feeding or growth.&#xD;
&#xD;
          2. History of bone, malabsorption, metabolic, congenital or chromosomal abnormality known&#xD;
             to affect feeding or growth.&#xD;
&#xD;
          3. Use of systemic antibiotics or anti-mycotic medication in the 4 weeks preceding&#xD;
             enrollment.&#xD;
&#xD;
          4. Known or suspected cows' milk protein intolerance / allergy, or lactose intolerance,&#xD;
             or severe food allergies that impact diet.&#xD;
&#xD;
          5. Current breast milk feeding in place of all other milk, and/or milk alternatives.&#xD;
&#xD;
          6. Clinical signs of severe micronutrient deficiencies.&#xD;
&#xD;
          7. Parents not willing / not able to comply with the requirements of study protocol.&#xD;
&#xD;
          8. Child's participation in another interventional clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Rosario Z. Capeding, MD</last_name>
    <phone>+63917 850 9788</phone>
    <email>lerosecap@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asian Foundation for Tropical Medicine, Inc.</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rosario Z. Capeding, MD</last_name>
      <phone>+63917 850 9788</phone>
      <email>lerosecap@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maria Rosario Z. Capeding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

